CME GroupCME +2.53%86 3-Year RORE % is -308.42 as of Mar. 2026. GuruFocus rates CME with a GF Score™ of 86/100 and a GF Value™ of $271.18 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 764 Capital Markets companies, CME Group ranks worse than 97.91% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
CME Group's 3-Year RORE % for the quarter that ended in Mar. 2026 was -308.42%.
The industry rank for CME Group's 3-Year RORE % or its related term are showing as below:
CME's 3-Year RORE % is ranked worse than 97.91% of 764
companies
in the Capital Markets industry
Industry Median: 15.115
vs CME: -308.42
CME Group (NAS:CME) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
CME Group 3-Year RORE % Related Terms
CME Group 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for CME Group's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Financial Data & Stock Exchanges subindustry, CME Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CME Group 3-Year RORE % vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CME Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where CME Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
CME Group (CME) has a 3-Year RORE % of -308.42 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CME Group and its competitors. According to the industry distribution chart, CME Group ranks #748 out of 764 companies in the Capital Markets industry, placing it in the top 97.9%.
Is CME Group's 3-Year RORE % too high?
CME Group's current 3-Year RORE % is -308.42. Based on the distribution chart, CME Group ranks #748 out of 764 companies in the Capital Markets industry, which is in the bottom quartile relative to peers. Overall, CME Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CME Group's 3-Year RORE % compare to MCO and ICE?
According to the Capital Markets industry distribution chart, CME Group ranks #748 out of 764 companies for 3-Year RORE %. This places CME Group in the lower half of its industry. The industry median 3-Year RORE % is 15.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Capital Markets company?
The median 3-Year RORE % among Capital Markets companies is 15.12, based on 764 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CME Group and its competitors. For the Capital Markets industry, the median 3-Year RORE % is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CME Group's current 3-Year RORE % is -308.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Modestly Undervalued. The stock's GF Value™ is $271.18, compared to a current price of $236.85 — trading 12.7% below its estimated fair value. The current 3-Year RORE % is -308.42. CME Group's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For CME Group (CME), the current 3-Year RORE % is -308.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CME Group (CME) Overvalued in 2026?
Based on GuruFocus' analysis, CME Group stock appears to be undervalued.
The current stock price of $236.85 is trading 12.7% below its estimated GF Value™ of $271.18.
GuruFocus considers CME Group to be Modestly Undervalued.
Key valuation signals for CME:
3-Year RORE %: -308.42
GF Value™: $271.18 vs. price of $236.85 (12.7% below fair value)
No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
86GF Score
Get the complete analysis for CME
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CME has been successfully added to your 
